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Abstract
Huntington disease (HD) is a severe neuropsychiatric disorder caused by a cytosine-adenine-guanine (CAG) repeat
expansion in the HTT gene. Although HD is frequently complicated by depression, it is still unknown to what extent
common HTT CAG repeat size variations in the normal range could affect depression risk in the general population.
Using binary logistic regression, we assessed the association between HTT CAG repeat size and depression risk in two
well-characterized Dutch cohorts─the Netherlands Study of Depression and Anxiety and the Netherlands Study of
Depression in Older Persons─including 2165 depressed and 1058 non-depressed persons. In both cohorts, separately
as well as combined, there was a signiﬁcant non-linear association between the risk of lifetime depression and HTT
CAG repeat size in which both relatively short and relatively large alleles were associated with an increased risk of
depression (β = −0.292 and β = 0.006 for the linear and the quadratic term, respectively; both P < 0.01 after adjustment
for the effects of sex, age, and education level). The odds of lifetime depression were lowest in persons with a HTT CAG
repeat size of 21 (odds ratio: 0.71, 95% conﬁdence interval: 0.52 to 0.98) compared to the average odds in the total
cohort. In conclusion, lifetime depression risk was higher with both relatively short and relatively large HTT CAG repeat
sizes in the normal range. Our study provides important proof-of-principle that repeat polymorphisms can act as
hitherto unappreciated but complex genetic modiﬁers of depression.
Introduction
Depression is one of the most common psychiatric
disorders with a lifetime prevalence of about 15%1.
Depression is accompanied by substantial morbidity and
mortality and, according to the World Health Organiza-
tion, it is currently the leading cause of disability world-
wide with an estimated 350 million people affected
globally2. In order to devise more effective therapeutic
and preventive strategies, a better understanding of its
pathogenesis is crucial. A vital step in elucidating the
pathogenesis of depression is to gain more insight into its
underlying genetic determinants. However, despite an
estimated heritability of between 30 and 50 percent of
major depression, genome-wide association studies
(GWAS) have only had limited success3. Although
recently a number of single-nucleotide polymorphisms
(SNPs) contributing to risk of depression were identiﬁed
in GWAS involving tens of thousands of subjects, the
effect sizes were very small and the inevitably large group
sizes harbor risks of bias due to both phenotypic as well as
genetic heterogeneity4,5.
One of the causes of the ‘‘missing heritability’’ problem
of depression may be that, aside from SNPs, GWAS are
unsuitable for detecting the contribution of other
important genetic polymorphisms, in particular variably
expanded DNA repeat sequences6–8. Expansions of simple
repeat sequences in genomic DNA have been associated
with many hereditary disorders9, but their association
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with common diseases is largely unknown. Among
expanded repeat disorders polyglutamine diseases are the
most prevalent9,10. These diseases are characterized by a
trinucleotide (cytosine-adenine-guanine (CAG)) repeat
expansion in the translated regions of otherwise unrelated
genes, resulting in proteins with expanded polyglutamine
domains10. The most common polyglutamine disease is
Huntington disease (HD), a debilitating neurodegenera-
tive disorder characterized by motor impairment, cogni-
tive decline as well as severe neuropsychiatric
disturbances of which depression is one of the most
prevalent11–13. It is caused by a CAG repeat expansion in
the Huntingtin (HTT) gene14. HTT alleles containing 40
or more CAG repeats lead invariably to HD, whereas
alleles with 36 to 39 repeats have incomplete penetrance.
Larger mutant CAG repeat size is associated with lower
age-of-onset and faster disease progression15–17. Inter-
estingly, mice transgenic for the HD gene also exhibit
depression-like behavior indicating that CAG repeat size
variations in this gene directly affect neuronal substrates
underlying mood regulation18–20.
Recently, it was shown that subjects with HTT alleles
containing CAG repeat lengths in the upper normal range
(i.e., the intermediate range with 27–35 repeats) experi-
enced signiﬁcantly more depressive symptoms, including
apathy and suicidal ideation, compared to control sub-
jects21–23. Moreover, a case–control study in patients with
major depression estimated the prevalence of incomple-
tely penetrant HTT alleles (36 to 39 CAG repeats) at
about 3 in 1000, whereas alleles in this range were absent
in the control group24. However, it is still unknown to
what extent more common length variations in the CAG
repeat tract of the HTT gene, ranging from 6 to 35 tri-
nucleotides, could affect lifetime depression risk. In the
current study, we, therefore, aimed to assess the con-
tribution of the whole spectrum of HTT CAG repeat
length variations to depression susceptibility using data
from two well-characterized Dutch cohorts: The Neth-
erlands Study of Depression and Anxiety and the Neth-
erlands Study of Depression in Older Persons25,26.
Methods and materials
Cohort 1
The Netherlands Study of Depression and Anxiety
(NESDA) is a cohort study among 2981 participants aged
18–65 years25. Participants were recruited from the gen-
eral population, general practices, and mental health care
institutes. This cohort includes 1973 subjects with a life-
time diagnosis of major depressive disorder (MDD) and/
or dysthymia (with MDD diagnosed in 1925 of these
participants), 635 subjects with a lifetime anxiety disorder
without lifetime depression and 373 healthy controls
without (a history of) psychopathology25. Diagnoses were
made according to the Diagnostic and Statistical Manual
of Mental Disorders Fourth Edition (DSM-IV) criteria
using the Composite Interview Diagnostic Instrument27.
Due to insufﬁcient DNA material for some subjects we
genotyped a total of 2738 participants (including 1808
depressed and 930 non-depressed persons) from this
cohort; however, the lacking DNA samples were missing
completely at random.
Cohort 2
The Netherlands Study of Depression in Older Persons
(NESDO) is a cohort study among 510 people aged 60–93
years recruited from both general practices and mental
health care institutes26. The cohort consists of 378
depressed (including 360 patients with MDD) and 132
persons (without a history of) psychopathology. In
NESDO the same methods were applied as in NESDA for
diagnosing depression26. Due to insufﬁcient DNA mate-
rial for some subjects we genotyped a total of 485 parti-
cipants (including 357 depressed and 128 non-depressed
persons) from this cohort; however, the lacking DNA
samples were missing completely at random.
Cohort 3
For external validation of our ﬁndings we extracted data
from a previously published study assessing the role of
incompletely penetrant HTT alleles in patients with
MDD24. This study included data on the distribution of
HTT CAG repeat lengths of 2986 chromosomes from
MDD patients and 4007 control chromosomes24. Because
we could not retrieve the raw data, data extraction was
performed from the published article using WebPlotDi-
gitizer (version 3.10)28.
Genotyping
We used a similar genotyping protocol as described
previously29. In brief, a polymerase chain reaction (PCR)
was performed in a TProfessional thermocycler (Biome-
tra, Westburg) with labeled primers ﬂanking the CAG
stretch of HTT (primer 1: ATGAAGGCCTTC
GAGTCCCTCAAGTCCTTC, primer 2: GGCGGTGGC
GGCTGTTGCTGCTGC) (Biolegio)30. The PCR was
performed using 10 ng of genomic DNA, 1x OneTaq
mastermix (New England Biolabs, OneTaq Hot start with
GC Buffer master mix), 1.5 µL of primer Mix A or B (table
A) and Aqua B. Braun water to a ﬁnal volume of 15 µL.
The PCR was performed with 30 cycles of 30 s dena-
turation at 94 ˚C, 1 min annealing at 60 ˚C and 2min
elongation at 68 ˚C preceded by 5min of initial dena-
turation at 94 ˚C and followed by a ﬁnal 5 min elongation
at 68 ˚C. Every PCR included a negative control without
genomic DNA, a reference sample of CEPH 1347-02
genomic DNA and two positive control samples with
predetermined 17/17 and 23/27 HTT CAG repeats. The
PCR products were run on either an ABI 3730 or an ABI
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3130 automatic DNA sequencer (Applied Biosystems) and
analyzed using the GeneMarker software version 2.4.0. All
assessments were done with cases and controls rando-
mized on plates and blinding with respect to disease
status information.
Statistical analysis
All data are displayed as means and 95% conﬁdence
intervals unless otherwise speciﬁed. In order to assess
whether HTT CAG repeat size is associated with risk of
lifetime depression we used binary logistic regression
analysis. First, to evaluate the presence of potential
interaction effects between the two HTT alleles or non-
linear effects of HTT CAG repeat size variations we used a
model with the presence of lifetime depression (i.e., MDD
and/or dysthymia) as the dependent variable and HTT
CAG repeat sizes in both alleles, a quadratic term for each
allele as well as a product term of the two alleles as
explanatory variables. As in this model only the quadratic
term of the longer allele appeared to be signiﬁcantly
associated with depression, we reduced the model to
contain only a main and a quadratic term for the longer
allele as independent variables. Exclusion of the shorter
allele hardly inﬂuenced the parameter estimates of the
longer allele. Therefore, for the sake of simplicity, from
here onwards we will take HTT to mean the longer of the
two alleles of each individual. We also adjusted the results
for the effects of sex, age and education level (coded as
‘‘basic’’, ‘intermediate’ and ‘‘high’’25,26) in order to assess
whether the effect of HTT CAG repeat size is independent
of these well-established risk factors for depression. The
Nagelkerke R2 was used to assess the proportion of
variability explained by the predictors in the model29. In
order to account for potential effects of points with high
leverage or inﬂuential points all statistical signiﬁcance
tests were based on robust estimators of standard errors.
Moreover, in order to analytically assess whether there
were any inﬂuential points of relevance that might have
affected our analyses, we also calculated the Cook’s dis-
tance, which indicated no major issues with inﬂuential
points. Furthermore, in order to assure that the results
were not unduly affected in case of deviations from model
assumptions and explore associations further, we also
applied a non-parametric method by calculating odds
ratios for a lifetime diagnosis of depression per HTT CAG
repeat size (collating alleles with repeat sizes of ≤ 16 or ≥
27 due to their relatively low frequency) compared to the
odds of lifetime depression in the total cohort using the
Fisher’s exact test. All tests were two-sided and sig-
niﬁcance level was set at P< 0.05. All analyses were per-
formed in SPSS version 23.0 (IBM SPSS Statistics for
Windows, IBM Corp).
Results
HTT CAG repeat size variations inﬂuence risk of lifetime
depression
The distribution of the HTT CAG repeat size in the
combined cohorts 1 and 2 is displayed in Fig. 1. In cohort
1 there was a signiﬁcant association between the risk of
lifetime depression and HTT CAG repeat size in which
the association was best represented by a model including
a quadratic term for HTT CAG repeat size (β=−0.239
and β= 0.005 for the linear and the quadratic term,
respectively; both P ≤ 0.044). Adjusting the analysis for the
effects of sex, age, and education level hardly changed the
results (β=−0.249 and β= 0.005 for the linear and the
quadratic term, respectively; both P ≤ 0.040). Similarly, in
cohort 2 there was a signiﬁcant quadratic association
between the risk of lifetime depression and HTT CAG
repeat size (β=−0.626 and P= 0.054 for the linear term;
β= 0.015 and P= 0.045 for the quadratic term), which
became slightly more pronounced after adjustment for the
effects of sex, age and education level (β=−0.788 and β
= 0.019 for the linear and the quadratic term, respectively;
both P ≤ 0.034).
Combining individual data from all subjects from both
cohorts further increased the statistical signiﬁcance of the
results (β=−0.292 and β= 0.006 for the linear and the
quadratic term, respectively; both P ≤ 0.009) after adjust-
ment for the effects of sex, age, and education level,
indicating that the effect of HTT on lifetime depression is
Fig. 1 Distribution of HTT CAG repeat sizes. The ﬁgure displays the
frequency distribution of the number of CAG repeats in the HTT gene
in 2165 subjects with and 1058 subjects without a lifetime depression
diagnosis, respectively
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independent of these risk factors (Fig. 2). Additional
adjustment for cohort (i.e., NESDA or NESDO) hardly
changed the statistical signiﬁcance of the ﬁndings (P ≤
0.008 for the linear and the quadratic term associated with
HTT CAG repeat size). To evaluate whether the effect of
HTT CAG repeat size is different for men and women, we
also tested for the interaction between sex and HTT CAG
repeat size. However, there was not a statistically sig-
niﬁcant interaction effect between sex and either the
linear term (P= 0.077) or the quadratic term (P= 0.069)
associated with HTT CAG repeat size, indicating that the
effect of HTT CAG repeat size on depression suscept-
ibility is the same for both men and women. Since our
control group included people with anxiety disorders
without co-morbid depression, we also performed a sen-
sitivity analysis by excluding these subjects from the
control group. This procedure did not materially change
the parameter estimates or their statistical signiﬁcance (β
=−0.363 and β= 0.008 for the linear and the quadratic
term, respectively; both P ≤ 0.006). Comparing the odds
ratios of lifetime depression per HTT CAG category
corroborated the results from the regression analysis and
indicated that the risk of lifetime depression is lowest in
individuals with a HTT CAG repeat size around 21 CAG
Fig. 2 HTT CAG repeat size is non-linearly associated with lifetime
depression risk. The red line indicates the model predicted mean
odds ratio for lifetime depression for each HTT CAG repeat size
(adjusted for age, sex, and education level): Both subjects with a
relatively low and a relatively high repeat size have a higher odds of
developing depression compared to the odds of depression in the
total group. Error bars indicate ± standard error. Please note that there
was only one subject (with depression) who had a HTT CAG repeat
size of 14 in the longer allele, therefore, no standard error could be
calculated for this CAG repeat category. Please also note that the
logistic model estimates of odds ratios for lifetime depression are
slightly different from those presented in Table 1 as these estimates
are obtained using data from all participants simultaneously, whereas
the estimates in Table 1 are calculated for each subgroup of HTT CAG
repeat size separately
Table 1 Distribution of the CAG repeat sizes in the longer
HTT allele
Repeat size Lifetime
depressiona
No lifetime
depressionb
Odds ratio (95%
conﬁdence
interval)c
≤ 16 51 19 1.31 (0.76 to 2.27)
17 532 242 1.07 (0.87 to 1.33)
18 414 188 1.08 (0.86 to 1.35)
19 257 139 0.90 (0.70 to 1.17)
20 208 104 0.98 (0.74 to 1.29)
21 121 83 0.71 (0.52 to 0.98)*
22 135 81 0.81 (0.59 to 1.12)
23 129 49 1.29 (0.90 to 1.85)
24 100 51 0.96 (0.66 to 1.39)
25 66 27 1.19 (0.74 to 1.92)
26 36 20 0.88 (0.50 to 1.55)
≥ 27 116 55 1.03 (0.72 to 1.47)
Total 2165 1058
aFigures represent the number of subjects per HTT category in the group with
lifetime depression
bFigures represent the number of subjects per HTT category in the group with
no lifetime depression
cThe odds ratio was calculated by dividing the odds of lifetime depression for
each CAG repeat category by the odds of lifetime depression in the total cohort
*P < 0.05 by the Fisher’s exact test in comparison to the reference category
Fig. 3 HTT CAG repeat size inﬂuences depression risk. The odds of
a diagnosis of lifetime depression is non-linearly associated with CAG
repeat size in the longer HTT allele: Both subjects with a relatively low
and a relatively high repeat size have a higher risk of developing
depression compared to the odds of depression in the total group.
Error bars indicate ± standard error. *P < 0.05 by the Fisher’s exact test
in comparison to the odds of lifetime depression in the total cohort
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repeats and increases with both lower and higher sizes of
the CAG tract in this gene (Table 1 and Fig. 3). The
Nagelkerke R2 associated with a model with only a linear
and a quadratic term for HTT CAG repeat size was 0.003,
indicating that HTT CAG repeat size variations can
account for 0.3% of the genetic variability of lifetime
depression on the observed probability scale. We also
derived the R2 on the liability scale as described pre-
viously31. Assuming that depression has a lifetime pre-
valence of about 15% in the Netherlands32 and adjusting
for the oversampling of patients with depression in our
cohort, the R2 on the liability scale was 0.004, indicating
that HTT CAG repeat size polymorphisms can account
for approximately 0.4% of depression heritability.
Calculation of odds ratios based on data from cohort 3
conﬁrmed a non-linear association between the risk of
MDD and the number of CAG repeats in the HTT gene
(Supplementary Fig. 1). However, because the data were
reported on a chromosome level, and not on an individual
level24, it was not possible to assess the effect of the
shorter and the longer HTT allele separately in this
cohort. In addition, because we could not reliably extract
the frequency of individual allele categories with relatively
rare repeat sizes of< 16 or> 27 from the article describ-
ing this cohort, we unfortunately could not perform a
regression analysis. For comparison, however, we also
analyzed our own data on chromosome level (i.e., com-
paring 4330 and 2116 chromosomes from patients with
depression and controls, respectively): This analysis again
conﬁrmed a quadratic association between HTT CAG
repeat size and risk of lifetime depression (β=−0.136 and
β= 0.003 for the linear and the quadratic term, respec-
tively; both P ≤ 0.023).
The prevalence of intermediate and incompletely
penetrant HTT alleles
In the combined cohorts 1 and 2, two individuals in the
group with lifetime depression had a HTT CAG repeat
size in the incompletely penetrant range (both with 37
repeats): one diagnosed with MDD and the other with
dysthymia. HD was, however, not diagnosed at the time of
assessment in either of them at the ages of 57 and 58
years, respectively. None of the subjects in the comparison
group had an HTT CAG repeat size in the mutant range.
The proportion of alleles with 27 CAG repeats or larger
was 0.053 (95% conﬁdence interval: 0.045 to 0.061) and
did not differ between participants with depression and
those without (P= 0.933).
Discussion
To the best of our knowledge this is the ﬁrst account of
an association between CAG repeat size variations in the
normal range of the HTT gene and risk of lifetime
depression. Although previously associations have been
reported between HTT CAG repeat size variations and
depression risk, these studies focused either on the
intermediate (i.e., 27–35 CAGs) or the incompletely
penetrant (i.e., 36–39 CAGs) range21–24. Importantly, we
found a non-linear relationship between CAG repeat size
in the longer HTT allele and risk of lifetime depression in
which both relatively short and relatively large alleles were
associated with an increased risk of depression as com-
pared to alleles containing around 21 to 24 repeats. Fur-
thermore, in accord with a previous study we found HTT
alleles in the incomplete penetrance range only in patients
with depression while these were absent in the compar-
ison group suggesting that some cases with depression in
the general population might possibly be due to incipient
HD24.
The presence of a curvilinear association between HTT
CAG repeat size in the normal range and depression risk
is intriguing as it suggests an optimal range of CAG repeat
sizes in the HTT gene supporting the idea that poly-
morphic tandem repeats could act as genetic ‘‘tuning
knobs’’ for evolutionary processes33. It is well-known that
very long CAG repeat expansions in the HTT gene are
associated with HD, which is accompanied by substantial
neuropsychiatric disturbances of which depression is one
of the most prevalent12,13. However, to date no disorders
have been formally associated with very short CAG repeat
tracts in the HTT gene. Although deletion of a terminal
band on the short arm of chromosome 4, the region
which contains the HTT gene, results in a distinct neu-
rodevelopmental disorder known as the Wolf-Hirschorn
syndrome and has been instrumental in localizing the
HTT gene, this deletion concerns multiple genes and has
not been associated with interruptions of the CAG repeat
tract in the HTT gene34. In accord with our ﬁndings most
population studies have found a minimum number of
nine CAG repeats in exon 1 of HTT24,35–37, suggesting
selection against alleles with very small number of repeats.
In this regard, it is also noteworthy that there is a ‘‘cliff’’ in
the frequency distribution of HTT CAG repeat sizes
between 16 and 17 repeats in our cohorts (Fig. 1), indi-
cating that HTT alleles with less than 17 repeats are much
less prevalent and, therefore, might be associated with a
survival disadvantage. Moreover, a recent study also
found that chromosomes from patients with bipolar dis-
order contained HTT alleles with signiﬁcantly shorter
CAG tracts than control chromosomes36. Although our
cohort did not include patients with bipolar disorder,
these ﬁndings are well in line with our results and suggest
that both relative extremes in short and long HTT CAG
tracts within the normal range could predispose to mood
disturbances. Moreover, while depression is very pre-
valent among HD mutation carriers38, the relation
between HTT CAG repeat size variations in either the
expanded or the normal range with depression risk has
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not been systematically investigated before in HD patients
or premanifest mutation carriers. Our ﬁndings, therefore,
suggest that it would also be interesting to investigate the
role HTT CAG repeat size variations as potential modi-
ﬁers of depression in HD mutation carriers.
We can only speculate about the mechanisms that could
account for the association between HTT CAG repeat size
variations and risk of depression. Huntingtin is essential
for normal embryonic development as targeted disruption
of its encoding gene is lethal in mice39. Although hun-
tingtin is expressed in many organs, its expression is
highest in the brain40. Huntingtin is in fact critical for the
development of the central nervous system since
decreased levels lead to reduced neurogenesis and pro-
found malformations of the cortex and striatum40. As the
expression of huntingtin is modulated by its poly-
glutamine tract40,41, the effect of HTT CAG repeat size
variations on depression might be due to altered endo-
genous levels of huntingtin. Importantly, huntingtin is a
key regulator of brain-derived neurotrophic factor
(BDNF)41. Reduced levels of BDNF have been consistently
associated with depression, whereas normalization of
BDNF levels has been reported following antidepressant
treatment42. However, we did not have data on blood or
cerebrospinal ﬂuid levels of BDNF in our participants,
therefore, whether small variations in HTT CAG repeat
size in the normal range could affect HTT or BDNF gene
expression remains to be investigated. Another mechan-
ism that might account for the association between HTT
CAG repeat size variations and risk of depression is the
polyglutamine-length-dependent interaction of hunting-
tin with a large number of other proteins40,43, including
several key transcription factors and co-activators such as
cAMP response element-binding protein (CREB) and
CREB-binding protein. These proteins are crucial for
neuronal function and synaptic plasticity, disturbances of
which have been implicated in depression pathogenesis44.
Interestingly, mice with a targeted deletion of the CAG
repeat tract of the HD gene exhibited defects in learning
and memory, further suggesting an important role for the
polyglumatine tract of huntingtin in central nervous sys-
tem function45. Finally, altered regulation of the
hypothalamic-pituitary-adrenal axis, which has been
involved in the pathogenesis of both HD and major
depression might play a role46–50. Although the precise
cellular pathways through which HTT CAG repeat poly-
morphisms could affect mood remain to be elucidated,
there are recent preliminary data showing an association
between HTT CAG repeat size variations across the
normal range and brain structure in healthy adults and
children51,52, suggesting direct structural modulation of
the brain as an underlying mechanism.
There are certain limitations to our study. First, a
potential limitation of our study is that we only used
samples from two Dutch cohorts in our main analyses.
Although by analyzing a homogenous population we
minimized the impact of population stratiﬁcation, this
might have consequences for the generalizability of our
ﬁndings. However, analysis of data extracted from a pre-
vious publication based on samples from American par-
ticipants conﬁrmed our ﬁndings and suggests that the
association between HTT CAG repeat size and depression
susceptibility is also likely to exist in other populations.
Second, there was a large difference in the age distribution
between the two cohorts in our study (i.e., 18–65 and
60–93 years in the NESDA and NESDO cohort, respec-
tively). It is of course possible that some of the younger
individuals who have not suffered from depression yet will
go on to develop depression in the future. However, it is
unlikely that this might have affected our ﬁndings as we
found the same non-linear association between HTT CAG
repeat size and the odds of depression in both cohorts.
Moreover, the results remained similar when we adjusted
for age in the combined cohort. Therefore, our ﬁndings
indicate that the association between HTT CAG repeat
size and depression is independent of age. Third, although
we did not have long-term follow-up data, it would be
interesting to follow-up participants with HTT alleles in
the incomplete penetrance range to assess whether, and
when, they go on to develop the full spectrum of HD signs
and symptoms. And ﬁnally, given our relatively limited
sample size, our primary analysis was based on the results
of the binary logistic regression including all the data
available, however, ﬂuctuating odds ratios per CAG repeat
size (Table 1 and Fig. 3) might reﬂect a more complex
relationship, which warrants further evaluation in larger
cohorts in the future.
In conclusion, we found a non-linear association
between CAG repeat size in the HTT gene and risk of
lifetime depression in which lifetime depression risk
increased with both relatively short and relatively large
alleles compared to alleles with CAG repeat sizes near the
center of the distribution. Our study provides important
proof-of-principle that repeat polymorphisms could act as
complex genetic modiﬁers of depression and thus may at
least partly account for its ‘‘missing heritability’’.
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